Terns Pharmaceuticals (Nasdaq: TERN) is gearing up for a major milestone. Ahead of Phase 1 data expected in Q4 2025, the company will host an investor educational webinar to highlight its lead oncology candidate, TERN-701, and its potential best-in-class profile in chronic myeloid leukemia (CML).
Why This Matters
CML has long been managed by tyrosine kinase inhibitors (TKIs). Yet resistance, intolerance, and long-term side effects leave patients in need of better options.
This is where TERN-701 steps in—a next-generation, oral, allosteric BCR-ABL inhibitor designed to target the ABL myristoyl pocket.
Webinar Details
- Topic: TERN-701 — Investor Educational Webinar
- Date: September 3, 2025
- Time: 4:30 p.m. ET
- Access: Register on Terns Investor Relations site
- Replay: Available on the website after the event
The session will be led by Terns leadership:
- Amy Burroughs – Chief Executive Officer
- Emil Kuriakose, M.D. – Chief Medical Officer
- Scott Harris – Chief Development Officer
About the CARDINAL Trial
Study design: Phase 1, multi-center, global trial (NCT06163430)
- Stage 1: Dose escalation – Completed Jan 2025 with no dose-limiting toxicities up to 500 mg QD.
- Stage 2: Dose expansion – Launched April 2025 with patients randomized to 320 mg or 500 mg QD (up to 40 patients per arm).
What’s next: Data readout in Q4 2025 will include 6-month major molecular response (MMR) rates, safety, and tolerability.
Early Signs Are Promising
- Compelling molecular responses were observed even at the lowest dose.
- Heavily pre-treated patients showed meaningful reductions in BCR-ABL transcript levels.
- Clean safety profile so far: no dose-limiting toxicities, no treatment-related discontinuations, no dose reductions.
If these trends hold, TERN-701 could offer a new standard of care in an evolving CML treatment landscape.
About Terns Pharmaceuticals
Terns is a clinical-stage biotech advancing small-molecule therapies for oncology and obesity.
Pipeline highlights:
- TERN-701 – Allosteric BCR-ABL inhibitor (CML)
- GLP-1 receptor agonist – Obesity
- THR-β agonist – Metabolic diseases
- Preclinical GIPR modulator program – With a GIPR antagonist in nomination
Takeaway: TERN-701 isn’t just another CML therapy in development. If the Phase 1 data delivers, Terns could position itself as a serious player in next-generation cancer therapeutics.
